Page last updated: 2024-08-18

allylamine and Dyslipidemia

allylamine has been researched along with Dyslipidemia in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS1
Levy, P1
Insull, W1
Armani, A; Toth, PP1
Davidson, MH1

Reviews

4 review(s) available for allylamine and Dyslipidemia

ArticleYear
Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus.
    Metabolic syndrome and related disorders, 2010, Volume: 8 Suppl 1

    Topics: Adult; Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dyslipidemias; Humans

2010
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.
    Southern medical journal, 2006, Volume: 99, Issue:3

    Topics: Allylamine; Bile Acids and Salts; Cholesterol; Colesevelam Hydrochloride; Colestipol; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Treatment Outcome

2006
Colesevelam hydrochloride in the management of dyslipidemia.
    Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:3

    Topics: Allylamine; Anion Exchange Resins; Anticholesteremic Agents; Azetidines; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Patient Compliance

2006
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:15

    Topics: Allylamine; Animals; Anticholesteremic Agents; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors

2007

Other Studies

1 other study(ies) available for allylamine and Dyslipidemia

ArticleYear
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
    Preventive cardiology, 2010,Summer, Volume: 13, Issue:3

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex

2010